COVID-19 in Kidney Transplantation: Epidemiology, Management Considerations, and the Impact on Kidney Transplant Practice

Ashish Kataria, MD, Idris Yakubu, PharmD, Ryan Winstead, PharmD, Madan Gowda, MD, and Gaurav Gupta, MD

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in the late 2019 as the cause of coronavirus disease 2019 (COVID-19), an acute respiratory viral illness. Patients with chronic underlying conditions may have an increased risk of morbidity and mortality from COVID-19. Kidney transplant recipients may be at a uniquely increased risk of serious complications from COVID-19 as compared to the general population because of a chronically immunosuppressed state and a high prevalence of comorbidities like diabetes, heart disease, and lung disease. Early data suggest that the mortality of patients on dialysis may be comparable to those with kidney transplants, although more research is needed. This concise review aims to describe the epidemiology of COVID-19 in kidney transplant recipients, manifestations, appropriate management, and clinical outcomes based on the available literature. Current evidence on many of the specific antiviral measures against COVID-19 has not shown a clear-cut benefit in smaller studies and the results of several ongoing larger clinical trials are awaited. In addition, we also highlight the impact of COVID-19 on kidney transplant center practice and volumes; potential living or deceased donors, recipients; and induction immunosuppression and surgical strategies.

Epidemiology in Kidney Transplant Patients

COVID-19 has shown widespread community spread across most countries. The exact prevalence of infection in the general population is unknown since the pandemic is ongoing; however, a case fatality rate of 2%–4% has been described. There is limited literature on the prevalence of COVID-19 in patients with end-stage kidney disease (ESKD) and how it compares to KTR. In 1 Chinese retrospective study among ESKD patients, the prevalence of COVID-19 was 2.1%. In another study from Italy, 15% (94/643) patients on maintenance dialysis were diagnosed with COVID-19. In a large study from New York, United States SOT recipients...
comprised 1% of all hospitalized patients with COVID-19. Although these data are not entirely comparable, they suggest that the incidence of COVID-19 in transplant patients is likely to be lower or at least similar to those on dialysis.

In recent studies from New York, the baseline demographic features of KTRs who had COVID-19 were similar to the nontransplant population. The median age at presentation was 50–60 y and a majority had underlying comorbidities including hypertension (>90%) and diabetes mellitus (>30%). The median duration to disease onset since transplant in these studies was 49 and 76 mo, respectively.

The average incubation period in the general population was reported to be between 5 and 7 d. The incubation period and reproduction number of COVID-19 in KTRs are not exactly known but may be similar to the general population. Contact tracing has identified confirmed exposure to a patient with COVID-19 in only 17% of KTRs in a study from New York. However, in a study from the general population from Wuhan, China, 64% of disease clusters were described among family members. Results in these 2 studies may be different because of different degrees of community spread in China and the United States. In addition, patient behavior (with regards to minimizing exposure to infected family members) may also impact these data. In the general population, viral replication typically begins 24–48 h before symptoms and peaks at 3–5 d after symptom onset. It has been suggested that compared to the general population, viral shedding may be prolonged to up to 28 d in patients with kidney transplants. Although it is not known whether this virus may be infectious or not, this has implications for patients with regards to return to work, for exposure to clinical environments, and to healthcare providers.

**DIAGNOSIS**

Reverse-transcription polymerase chain reaction (RT-PCR) assay of upper respiratory secretions usually collected with a nasopharyngeal swab is the current diagnostic test of choice for COVID-19 patients. This test is >99% specific, although sensitivity may vary by severity of disease, specimen type, and assay type. False negatives of up to 30% have been reported although retesting on successive occasions may increase the positive yield. In a study of 90 SOT recipients from New York, 8% patients had an initial negative upper respiratory RT-PCR result. The yield of lower respiratory tract specimens has been shown to be higher and this is likely true for transplant patients also.

Rapid tests using RT-PCR with point-of-care results for SARS-CoV-2 detection are also becoming available. Mobile platforms like Abbot ID NOW molecular point-of-care device typically run 1 sample at a time and are useful for bedside testing and to perform tests in remote areas. Facility-based platforms like Cepheid GeneXpert Xpress have higher throughput and yield results in less than an hour. In many cases, a presumptive diagnosis may have to be made based upon the clinical picture, characteristic laboratory and lung imaging findings. Serologic IgM and IgG antibody testing is becoming widely available but the indications, validity, and reliability of these tests remain largely unknown. Most of the studies in general population suggest a rapid formation of IgM and/or IgG within a few days of COVID-19 infection, although there is no data to date to suggest that seroconversion confers definitive immunity to future reinfection. Nevertheless, the rates of reported reinfection rates remain extremely low. In addition, emerging data suggest some efficacy for convalescent sera transfusions for patients with serious COVID-19 infections. Data on seroconversion among immunosuppressed kidney transplant patients are not available at this time.

Laboratory findings have been generally similar in KTR and nontransplant population. The white cell counts (median 4800–5300/mm³) and platelet counts were within normal limits. However, a relative lymphopenia (median 600–800 lymphocytes/mm³) was more common. Serum ferritin (median 407–1230 ng/mL) and erythrocyte sedimentation rate (median 40 mm/h) were significantly elevated in these studies. The interleukin-6 (IL-6) level was only slightly elevated in these studies (median range 20–24 pg/mL), although it has been noted to be significantly elevated in a few patients. Chest imaging showed variable findings that could include normal/mild focal infiltrates in 33% and diffuse patchy infiltrates in nearly half the patients.

**MANIFESTATIONS AND CLINICAL OUTCOMES**

In the general population, COVID-19 could manifest with varying degrees of severity ranging from asymptomatic/mild self-limited infections (~80%) to all the way to severe (14%) and critical ventilator-dependent (5%) illness. Similarly, KTRs with COVID-19 can have varying clinical manifestations and severity, ranging from mild or asymptomatic infections to multiorgan failure resulting in death. The onset of symptoms has ranged widely from 1 d to 3 wk before the diagnosis. In 1 study on KTRs, fevers were noted to be less common (58%) compared with studies from the general population. Although the initial study by Zhu et al from Wuhan in SOT recipients described disease severity according to the Chinese CDC classification, other disease severity classifications have been used by other authors (Table 1). In the study from New York by Pereira et al, 44% of 46 KTRs had critical and 34 (54%) had mild to moderate disease. On the other hand, in the Wuhan study, 8 of 10 KTRs (80%) had moderate–severe disease. In 2 separate studies from New York, 78% KTRs required hospitalization and 34% required ICU stay. The median length of hospital stay has ranged from 4.5 d to a much longer duration in another study with 43% KTRs still hospitalized at a 3-wk period. In a newly published study from New York on the outpatient management of COVID-19, of 41 patients, 13 patients (32%) required hospitalization a median of 8 d (range, 1–16) after symptom onset, and 23 (56%) had outpatient symptom resolution a median of 12 d (4–23) after onset.

Despite the heterogeneity of case descriptions, it does appear that the incidence of severe complications of COVID-19 may be higher in KTRs than the general population in various studies. These complications may include acute respiratory distress syndrome (ARDS) requiring mechanical ventilation (27%–39% patients) and severe acute kidney injury that necessitated the initiation of dialysis (20%–40%). The median time to intubation was reported as 5 d posthospitalization in 1 study. Other reported complications include rhabdomyolysis, myocarditis, bacterial superinfection, and atrial fibrillation.
Early data from the general population suggest that COVID-19 may cause viral infection of different renal cells resulting in nephritis. SARS-CoV-2 uses the receptor angiotensin-converting enzyme 2 (ACE2) for cell entry; both endothelial cells and podocytes express ACE2. Glomerular changes and nephritis-like histology have been described in postmortem samples from patients with COVID-19. A case series from the general population reported that >40% of cases had proteinuria on hospital admission. Acute kidney injury (AKI) has also been reported to be common among critically ill patients with COVID-19. A case series from the general population reported that >40% of cases had proteinuria on hospital admission. Acute kidney injury (AKI) has also been reported to be common among critically ill patients with COVID-19.

The limited literature from kidney transplants suggests a similar or a higher incidence of AKI as well as proteinuria. These data are limited by the absence of previous baseline parameters to clarify whether proteinuria was a new onset. Similarly, it is unclear whether the AKI is secondary to hemodynamic alterations or a direct infection by SARS-CoV-2. An interesting case report from a kidney transplant patient showed evidence of endothelialitis in the transplanted kidney. It is unknown whether COVID-19 may be immunomodulatory and trigger acute rejection. It is, however, plausible that the cytokine release syndrome (CRS) associated with COVID-19 combined with a reduction in IS medications may predispose KTR to AR.

### Outcomes

Various estimates of morbidity and mortality among KTR have been described in the literature. In general, outcomes seem to be worse than those described in the general population. Although adequate data are not available, early reports suggest that the mortality of COVID-19 may be
similar between dialysis-dependent ESKD patients and kidney transplant patients. Xiong et al\textsuperscript{12} reported 33 (or 130; 23\%) Chinese transplant patients with ESKD had severe or critical disease and a significant proportion of the patients (43/130; 33\%) died of complications.\textsuperscript{12} Two other studies (1 each from Spain and Italy) also describe a mortality of 29\%–30\% among maintenance dialysis patients.\textsuperscript{3,12} The 3 studies from New York in kidney transplant patients reported a mortality of between 16\% and 30\%.\textsuperscript{4,14,43}

There are 2 ongoing registry studies that may further clarify the outcomes of kidney transplant patients with COVID-19. The first one is an international COVID-19 Solid Organ Transplant Registry (www.C19TxR.org).\textsuperscript{44} As of May 20, 2020, a total of 592 SOT patients have been reported. A majority of these were reported from the United States and the United Kingdom. Of these 592, 530 (90\%) were in kidney transplant patients. Among the 405 KTRs that had received treatment, 46 (15\%) have recovered and 58 (14\%) died. Another registry study being organized by the University of Washington is actively collecting data. Although published data are not yet available, >300 kidney transplants with COVID-19 were reported to the registry to date.

**MANAGEMENT**

**Specific Antiviral Measures**

Specific antiviral or immunomodulatory agents against COVID-19 are being rapidly investigated and many are currently being used in approved or experimental settings in the general population. Although a detailed review of these agents is beyond the scope of this article, various agents with their proposed mechanisms of action are listed in Table 2. It should be noted that no single agent has proven to be successful and had reproducible results in long term trials. A summary of the published studies, IS alterations, and other interventions focusing only on kidney transplants is described in Table 3.

One of the first publicized agents against COVID-19, hydroxychloroquine (HCQ) with or without azithromycin, was investigated because of its potential direct antiviral and immune modulation properties.\textsuperscript{45} Although a few studies with small sample sizes appeared to have promising results,\textsuperscript{46} a randomized, controlled trial of 150 Chinese patients showed no significant difference in the 28-d negative conversion rate between treatment and the control groups.\textsuperscript{47}

Tocilizumab, an IL-6 antagonist is being used in patients with COVID-19 in an effort to suppress the CRS.\textsuperscript{48} In a single series of 21 patients with severe COVID-19 pneumonia without controls, a single dose of 400 mg tocilizumab showed promising results with faster resolution of fevers, hypoxia, and earlier extubation.\textsuperscript{49} Several randomized controlled trials are currently being performed to investigate the role of IL-6 blockade in the treatment of COVID-19. Tocilizumab (and other IL-6 blockers) has been tried with variable success in KTRs with moderate–severe disease or in patients with high IL-6 levels.\textsuperscript{50} Whether additional immunosuppression with IL-6 blockade would provide increased benefit in immuno-suppressed KTRs is controversial and a subject of ongoing research. It is contraindicated in patients with a suspected or proven coinfection with bacterial or fungal agents and it should be individualized in KTRs in which benefits outweigh the risks.

Remdesivir, a RNA polymerase inhibitor, is also being intensely investigated.\textsuperscript{51} Early data from studies in the general population suggest that it may be beneficial in patients with mild–moderate disease, but the data for those with severe or critical disease are less clear.\textsuperscript{52-54} There is no data on a possible drug interaction between Remdesivir and calcineurin inhibitor (CNI), making this an attractive choice, although access to the drug is currently limited and there is lack of safety data for patients with a poor kidney function (glomerular filtration rate <30 mL/min/1.73 m\textsuperscript{2}).\textsuperscript{55}

In KTRs, other specific antiviral medications have been used with variable success rates in several case series and reports from China and Europe. Several papers reported the use of the protease inhibitor combination of Lopinavir and Ritonavir.\textsuperscript{33,56,57} In addition to an unlikely efficacy, their interaction with CNI metabolism suggests that this combination should not be used for the treatment of COVID-19 in KTRs.\textsuperscript{58} Additionally, there is no proven benefit (and potential harm) of other agents such as intravenous immunoglobulin, interferon, HCQ, and azithromycin in KTRs except in anecdotal cases and their routine use is not recommended.\textsuperscript{59}

Very early data from the general population suggest some efficacy for convalescent sera transfusions for patients with serious COVID-19 infections, although no such data are available yet for KTRs or other immunosuppressed patients.\textsuperscript{22-31}

**Maintenance Immunosuppression Management**

The management of IS agents in KTRs is complex because the appropriate choice or optimal dosing of individual agents remains mostly unclear. Transplant clinicians have generally extrapolated the evidence in managing other life-threatening infections in KTRs to COVID-19, which involves a reduction of overall IS.\textsuperscript{60}

The primary aim of IS management in SOT recipients is a balance between the risk of rejection and complications of overimmunosuppression, such as worsening of COVID-19 complications and superinfections. KTRs with COVID-19 should have their IS management reduced based on factors such as age, time since transplant, sensitization level, previous rejection episodes, and the severity of COVID-19. It has been hypothesized that CNIs can lead to immune modulation against the virus and thus may be beneficial in reducing the cytokine release storm that is frequently seen with COVID-19.\textsuperscript{43} Thus, cautious reduction rather than complete elimination of immunosuppression may avoid precipitation of severe complications like ARDS. This, however, remains to be proven in clinical studies.

Here, we propose an algorithm based upon our own experience as well as from published studies.\textsuperscript{5,7,33,43,62-64} Patients with mild COVID-19 (minimal or no supplemental O2 requirement) may benefit from reduction in their target CNI trough concentration to ~75\% of their previous goal. In addition, reduction of other agents such as antimetabolites (mycophenolate or azathioprine) by 50\% should be considered. Those with moderate–severe disease may benefit from further reduction in IS with target CNI trough goals to ~25\%–50\% and temporary cessation of their antimetabolites. Steroid dosage ideally should be left unchanged in patients with mild–moderate disease. In those with critical disease (ARDS or requiring mechanical ventilation), consideration may be given to intravenous methylprednisolone or hydrocortisone in an attempt to suppress CRS, although there is inadequate evidence to
support this practice. Patients who have a rapid clinical deterioration to ARDS or septic shock may need withdrawal of all immunosuppression, especially if they are coinfeeted with other organisms and/or stress dose steroids are being concomitantly administered. Patients on maintenance belatacept may need to have their monthly dose held especially if they have moderate or severe disease. Therapy could generally be resumed on their previous monthly schedule once they are symptom free. For patients that have recovered, it remains unknown whether and when the CNI and antimetabolite dose should be increased back to baseline. Extrapolation from the management of other infections suggests that it should be reasonable to cautiously reinstitute the preinfection IS regimen once the patients starts improving clinically.

**Renin–Angiotensin–Aldosterone System Inhibitors**

SARS-CoV-2 enters human cells by binding of its viral spike protein to the membrane-bound form of the monocarboxy-peptidase ACE2. Studies in animals have suggested that ACE inhibitors and angiotensin-receptor blockers (ARBs) may upregulate ACE2 expression, thus increasing the availability of target molecules for SARS-CoV-2. These considerations led to speculation that ACE inhibitors and ARBs might be harmful in patients with COVID-19. Despite this, there are now evolving data to suggest that this may not be true and in fact there may be some benefit to RAAS blockade. Thus, stopping RAAS blockade in patients with COVID-19 cannot be recommended.

**Anticoagulation and Complement Blockade**

Thrombophilia has been commonly associated with COVID-19 and various postmortem studies have shown the presence of macrothrombi and microthrombi in both venous and arterial systems. Critically ill COVID-19 patients have been reported to have significant elevation in D-dimer levels and a very high risk of deep venous and pulmonary thromboembolism of up to 30%. Various approaches to the prevention of thromboses ranging from prophylactic to therapeutic anticoagulant strategies are being employed and are described elsewhere. At this time, there is no evidence to suggest that kidney transplant patients are at an increased risk of thrombotic events compared with the general population for disease of similar severity. Thus, we recommend standard prophylactic anticoagulant with low-molecular heparin (adjusted for renal function) or unfractionated heparin for hospitalized KTR with no active thromboses. Some authors describe the use of direct thrombin inhibitors among patients with severe disease and D-dimer >3 μg/mL.

Complement is an integral component of the innate immune response to viruses and an instigator of proinflammatory responses. A recent study of SARS-CoV, which is closely related to SARS-CoV-2, found that activation of complement component C3 exacerbates disease in SARS-CoV–associated ARDS. Although there are numerous pathways for renal injury due to coronavirus, complement activation may play a significant role. Case reports describing renal endothelitis and thrombotic microangiopathy support this association. Currently, there are no published data on the effect of complement inhibitors, but there are several ongoing clinical trials that may shed some light on the topic.

### Table 2

| Agent | Mechanism of action |
|---|---|
| Remdesivir | Interference with viral RNA-dependent RNA polymerase; premature termination of viral RNA transcription. |
| IL-6–specific antibodies | Competitively inhibit IL-6 or IL-6 receptor thereby inhibiting signal transduction involved in cytokine release syndrome. |
| Corticosteroids | Glucocorticoid receptor interactions with transcription factors, especially activator protein 1 and NF-κB. |
| Hydroxychloroquine/chloroquine | Reduces cytokine production, especially IL-1 and IL-6; intracellular alkalization inhibits pH-dependent steps of viral replication as well as viral receptor glycosylation. |
| Azithromycin | Antibacterial mechanism is largely unknown. |
| ACE/ARB | Potentially may mitigate ACE2 downregulation caused by viral binding to the enzyme. |
| Lopinavir/ritonavir | May inhibit chymotrypsin-like protease (3CLpro). |
| Favipiravir | Nucleoside analog prodrug, RdRP inhibitor. |
| Eculizumab | Inhibits cleavage to C5a and C5b and prevents the generation of the terminal complement complex C5b-9, which is involved in cell lysis. |
| Plasma | Hosts development of pathogen-specific antibodies allowing for immune-mediated neutralization and clearance of pathogen. |
| Systemic anticoagulation | May mitigate the inflammatory response and subsequent hemostatic abnormalities such as venous thromboembolism, myocardial infarction, and disseminated intravascular coagulation. |
| In vitro data, animal data, and hypothetical treatments | |
| Ivermectin | Wide antiviral activity by nuclear transport inhibition. |
| Ribavirin | Direct antiviral activity via inhibition of RNA polymerase chain termination, inhibition of RNA capping activity, and lethal mutagenesis of RNA genome. |
| Nitazoxanide | Interferes with pyruvate ferredoxin oxidoreductase enzyme-dependent electron transfer reaction, which is essential to anaerobic metabolism. |
| Zinc | May reduce RNA synthesis catalyzed by an RdRP. |
| Interferon | May bind to specific plasma membrane receptors and activate JAK-STAT signaling pathway. |
| Doxycycline | Anti-inflammatory via inhibitory action on metalloproteases and modulating effects of proinflammatory cytokines IL-6, IL-8, and tumor necrosis factor-alpha. |
| Anakinra | Blocks biological activity of IL-1α and IL-1β. |

ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; COVID-19, coronavirus disease 2019; IL, interleukin; RdRP, RNA-dependent RNA polymerase.
| Author                  | Sample size | Country of origin | Change in immunosuppression                                                                 | Antiviral treatment                | Immunosuppressive changes                         | Outcomes                                      |
|-------------------------|-------------|-------------------|-----------------------------------------------------------------------------------------------|------------------------------------|--------------------------------------------------|-----------------------------------------------|
| Pereira et al5a         | 46b         | New York City, USA| Hospitalized patients (75%) CNI dose decreased or held (18%) Antimetabolite reduction or held (87%) Corticosteroids decreased or held (7%) | Azithromycin (66%) Bolus steroids (23%) Tocilizumab (20%) | Hospital admissions (75%) | ICU admission (34%) Mortality (27%) Discharged from the hospital (54%) Hospital readmissions (1%) |
| Alberici et al 99       | 20          | Brescia, Italy    | Complete withdrawal of CNIs and antimitobalites. All patients received methylprednisolone 16 mg daily or prednisone equivalent | HCQ (95%) Dexamethasone (55%)     | ICU admission (20%) Treated on general ward (60%) Mortality (20%) Discharged from the hospital (15%) Hospital admissions (78%) |
| Akalin et al6           | 36          | New York City, USA| Withdrawal of antimitabolites (67%) Withdrawal of tacrolimus (17%)                             | HCQ (67%) Leronlimab (CCR5 antagonist; 17%) Azithro (36%) Tocilizumab (5%) Intubation required (30%) Mortality (28%) | ICU admission (20%) Treated on general ward (60%) Mortality (20%) Discharged from the hospital (15%) Hospital admissions (78%) |
| The Columbia University Kidney Transplant Program14 | 15          | New York City, USA| Antimitabolite discontinuation (71%) Prednisone decreased (10%) Belatacept infusion postponed (1/2; 50%) Discontinued all immunosuppression (13%) No change in immunosuppression (7%) Replaced tacrolimus and MMF with prednisone (7%) | HCQ plus Azithro (60%) | ICU admission (27%) Mortality (14%) Discharged from the hospital (53%) |
| Nair et al43            | 10          | New York City, USA| MMF discontinuation (89%) Discontinue tacrolimus (9%) Discontinue sirolimus (1/1) No changes (10%) | HCQ plus Azithro (90%) None reported | ICU admission (100%) |
| Fernandez-Ruiz20        | 8           | Madrid, Spain     | MMF discontinuation (4/5; 80%) Reduction in tacrolimus (6/7; 86%) Discontinuation of prednisone (2/8; 25%) Reducing tacrolimus dose, stopping MMF | Lopinavir/ritonavir plus HCQ (100%) Methylprednisolone (38%) | ICU admission (30%) Mortality (30%) Discharged from the hospital (70%) Hospital admissions (100%) |
| Banerjee et al7         | 7           | London, UK        | None reported                                                                                   | None reported                     | ICU admission (100%) |
| Kates et al71%          | 1           | Wisconsin, USA    | Reduced tacrolimus dose, MMF stopped, prednisone 10 mg daily started                              | HCQ + Azithro                     | None reported                                   | Hospitalized and discharged from the hospital |
| Zhong et al21          | 1           | Wuhan, China      | Discontinued MMF                                                                               | Oseltamivir                      | Intravenous immune globulin                     | Hospitalized, discharged home and symptoms resolved |
| Meziyerh et al32        | 1           | Leiden, Netherlands| Everolimus and pred continued                                                                  | Lopinavir/ritonavir plus HCQ      | None reported                                   | Hospitalized and discharged from the hospital |
| Marx et al34            | 1           | Strasbourg, France| MMF discontinuation, belatacept held and switched to cyclosporine, prednisone continued        | None reported                     | None reported                                   | Hospitalized and discharged from the hospital |

aData only on hospitalized patients.

bStudy included non-kidney transplant recipients. Sample size is kidney transplant recipients only, but therapies and outcomes reported includes overall cohort of all solid organ transplant recipients. Azithro, azithromycin; CNI, calcineurin inhibitor; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil.
Augmentation of Immune System, Specific Immunotherapy, and Adoptive Immune Therapy

Although a functional immune system is essential for combating infection, the role of augmenting the immune response is still unclear. Several vitamins, nutrients, and cofactors are thought to improve immune function. For example, zinc-deficient patients may be at an increased risk of viral infections.76 It seems reasonable to test for deficiencies and provide supplementation to those patients, but there are no data on safety and efficacy of these approaches.

Specific immune therapies such as the use of convalescent plasma have been met with early success,77 and larger studies are underway. Other directions in future therapeutics include the use of monoclonal antibodies against the viral spike protein80 and adoptive T cell therapy. Adoptive T cells with a chimeric antigen receptor or a T-cell receptor have been successfully developed against other viruses like Epstein barr virus81 and severe acute respiratory syndrome coronavirus-1.82 Use of adoptive T cell therapy may be particularly helpful in SOT recipients with COVID-19 in reducing the risk of serious complications and are in the developmental stage (https://www.fiercebiotech.com/research/scientists-explore-using-engineered-t-cells-to-target-covid-19).

Future Trials and Vaccines

The race for a successful vaccine has been going on for several months now, and several candidate vaccines ranging from mRNA to DNA vaccines and from injectables to tablets are in initial planning or early testing phases.83 Historically, vaccine deployment is delayed in the immunocompromised because of concerns of safety and efficacy and this remains an area of active concern in protecting KTRs from COVID-19. Similarly, there is a lack of planned interventional clinical trials focused on transplant patients. A review of the US and European clinical trial databases (www.clinicaltrials.gov and https://eudraCT.ema.europa.eu) reveals only 10 listed studies, all of which are observational in design. Some of these key studies are listed in Table 4.

Impact on Induction Immunosuppression Strategies

COVID-19 patients have been reported to develop profound lymphopenia. Akalin et al8 reported infected KTRs had

| TABLE 4. | List of ongoing clinical studies on COVID-19 among transplants |
|----------|-----------------------------------------------------------|
| Study features | Intervention and primary outcome (s) | Current status |
| Blood innate biomarkers (IL-6) as predictors of COVID-19 disease progression in recently infected KTRs | Intervention: quantity of IL-6 in of whole blood samples after ex vivo costimulation with lipopolysaccharide and adenosine triphosphate in COVID-19 kidney transplant patients | Recruiting |
| ClinicalTrials.gov Identifier: NCT04369456 | Outcome: clinical outcomes | |
| N = 115, single intervention arm | | |
| Multicentric | | |
| AlloSure guided immuno-optimization for COVID-19: an early experience | Patients with solid organ transplants who have been admitted with suspected COVID-19 utilizing AlloSure donor derived cell-free DNA to help guide immunosuppression management balancing the treatment of sepsis and avoiding allograft rejection | Not yet recruiting |
| ClinicalTrials.gov Identifier: NCT04341103 | | |
| N = 500, observational | | |
| Multicentric | | |
| A prospective noninterventional study to evaluate the role of immune and inflammatory response in recipients of allogeneic hematopoietic stem cell transplantation (SCT) affected by severe COVID-19 infection | Comparison of inflammatory/immunological biomarkers <72 h after development of oxygen requirement | Active, not recruiting |
| ClinicalTrials.gov Identifier: NCT04349540 | | |
| N = 40, observational, single-center | | |
| Assessment of the impact of COVID-19 on transplant patients and on patients awaiting transplantation | Surveys to be distributed to patients awaiting transplantation | Recruiting |
| ClinicalTrials.gov Identifier: NCT04376775 | | |
| N = 2000, observational, multicentric | | |
| COVID-19 in liver transplant recipients in Spain: a nationwide prospective study | Incidence, clinical characteristics, and outcomes in liver transplant patients | Recruiting |
| ClinicalTrials.gov Identifier: NCT04361591 | | |
| N = 400, observational, multicentric | | |
| Development and persistence of humoral immunity against SARS-CoV2 in liver transplanted patients in comparison with immunocompetent patients | Incidence, titration, and evolution of IgG and IgM in a prospective cohort of liver transplant patients surviving to the first wave of COVID-19, in comparison to not immunosuppressed patients | Recruiting |
| ClinicalTrials.gov Identifier: NCT04410471 | | |
| N = 300, observational | | |
| COVID-19 research in organ transplant recipients | Clinical, immunological response, and seroconversion kinetics for COVID | Not yet recruiting |
| ClinicalTrials.gov Identifier: NCT04407221 | | |
| N = 1100, observational | | |
| Consequences of the COVID-19 pandemic on worldwide organ procurement and transplantation | Organ transplantation activity during COVID | Recruiting |
| ClinicalTrials.gov Identifier: NCT04416256 | | |
| N = Observational 230 000 | | |

COVID-19, coronavirus disease 2019; IL-6, interleukin 6; KTR, kidney transplant recipient; SARS-CoV2, severe acute respiratory system coronavirus 2; SCT, stem cell transplantation.
lower CD3, CD4, and CD8 cell counts and more rapid clinical progression than persons with COVID-19 in the general population. It is unclear if the increased mortality in KTRs noted in this study (as opposed to the general population) was due to the overall frailty of the transplant patients or due to the impact of IS drugs, for example, the use of T-cell depleting induction agents that are the standard of care in a majority of the US kidney transplant centers. Although no definite recommendations can be provided, in case induction immunosuppression is indicated, it seems reasonable to consider non–T-cell depleting agents (basiliximab or other IL2 receptor antagonists), especially in low immunologic risk kidney transplant patients wherein the risk of acute rejection is lower and the risk of COVID-19 is significant based upon population characteristics.

IMPACT OF COVID-19 ON KIDNEY TRANSPLANT CENTER VOLUME

After the COVID-19 outbreak, a significant decline (25%–90% reduction) in both deceased donor and living donor kidney transplants was reported by several hyper endemic countries including Italy, France, and the United States.84-86 Surprisingly, a reduction in transplantation rates was noted even in regions where COVID-19 cases are low, suggesting a global and nationwide effect beyond the local COVID-19 infection prevalence. Many transplant programs reported using a staged approach to transplant volume considerations with suspension of living donor surgeries and limitation of deceased donor transplants because of the risk of transmission to procuring teams, kidney donors, and kidney recipients.87 Transplant professionals will continue to need to adapt to these rapidly changing circumstances, and remain poised to reinvigorate transplant infrastructure to avoid losing opportunities to transplant valuable deceased donor organs.

RISKS OF DONOR TRANSMISSION TO RECIPIENTS AND SURGICAL TEAMS

At this time, there are no confirmed reports of transmission of SARS-CoV-2 from a live or deceased donor to the recipient.88 Theoretically, viral transmission could happen via donor blood or the organ itself. Limited data have shown that viral RNA could be detected in plasma or serum from COVID-19 patients. In the first 41 patients in the city of Wuhan, viremia was found only in 6 of 41 (15%) patients.89 The following points may be relevant to considerations regarding organ transplantation: (1) viral RNA in plasma or serum could be detected in COVID-19 patients on the first 2 or 3 d after the onset of symptoms; (2) most patients, especially younger adults who can donate organs, had milder symptoms than the older adults; and (3) the rate of infectivity of patients who are in the incubation period remains uncertain, and there are no data on the viral load in plasma, serum, or lymphocytes among individuals in the incubation period. Despite this, there are no reported cases of transfusion transmission of SARS-CoV-2 to date. Nevertheless, COVID-19 testing for all asymptomatic live kidney and most deceased donors before transplantation is currently being recommended, especially when the turnaround time is reasonable.90 However, its impact on organ utilization rates and actual transmission is unknown owing to the presence of false negatives. The use of chest computerized tomography scans on deceased donors who test PCR negative should be based on individual donor’s history and the level of community spread.

The virus has been isolated in the kidney and urine of some COVID-19 patients, and thus, the use of deceased organs with diagnosed COVID-19 patients remains controversial.91,92 Of particular relevance are laparoscopic living donor procurements and transplant surgeries. It has been theorized that the pneumoperitoneum induced during a laparoscopic procedure may increase the risk of aerosolization of COVID-19.93 Thus, routine testing for COVID-19 with nasopharyngeal swabs before all elective surgeries is rapidly becoming the norm in many hyperendemic areas.

CONCLUSIONS AND THE FUTURE

Various transplant organizations have published best practice guidelines to guide transplant programs during the pandemic and to minimize the spread of COVID-19 to living donors, recipients, and the treating providers.87,94 Transplant programs will need to individualize their approaches in navigating through individual aspects of transplant operations by prioritizing patients requiring urgent transplantation, carefully selecting which organ offers to accept (local donors, avoiding long travel of the procuring team, and minimizing delayed graft function to reduce the recipient’s hospital stay), enhancing tele-visits for stable outpatients,95 establishing care triage systems, and balancing the risk of excessive immunosuppression against allograft rejection. The COVID-19 pandemic has resulted in unprecedented challenges that include unclear efficacy of current investigational therapies in transplant populations, lack of data driven optimal immunosuppression management, historic delay in vaccine deployment for immunocompromised hosts related to safety or efficacy, and ethical dilemmas in organ allocation and healthcare resource constraints.

REFERENCES

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; doi:10.1001/jama.2020.2648
2. Mahase E. Covid-19: UK death toll overtakes Italy’s to become worst in Europe. BMJ. 2020;369:m1850. doi:10.1136/bmj.m1850
3. Johns Hopkins University and Medicine Coronavirus Resource Center. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. 2020. Available at https://coronavirus.jhu.edu/map.html. Accessed May 12, 2020.
4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–2059. doi:10.1001/jama.2020.6775
5. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20:1800–1808. doi:10.1111/ajt.15941
6. Akalin E, Azzi Y, Barash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020;382:2475–2477. doi:10.1056/NEJMc2011117
7. Banerjee D, Popoola J, Shah S, et al. COVID-19 infection in kidney transplant recipients. Kidney Int. 2020;97:1076–1082. doi:10.1016/j.kint.2020.03.018
8. Zhang J, Litvinova M, Wang W, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. Lancet Infect Dis. 2020;20:793–802. doi:10.1016/S1473-3099(20)30230-9
9. Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26:506–510. doi:10.1038/s41591-020-0822-7
65. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280.e8. doi:10.1016/j.cell.2020.02.052
66. Soler MJ, Bluth B, Haferkamp C, Oliva R, et al. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep. 2008;10:410–414. doi:10.1007/s11906-008-0076-0
67. Fang L, Karakülakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21. doi:10.1016/S2213-2600(20)30116-8
68. Vadvanaranathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382:1653–1659. doi:10.1056/NEJMms2005760
69. Menter T, Hashbauer JD, Nienhof R, et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and varied findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020. doi:10.1111/his.14134
70. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill COVID-19 patients with COVID-19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013
71. Ciarella A, Peyvandi F, Martinelli I. Where do we stand with antithrombotic prophylaxis in patients with COVID-19? Thromb Res. 2020;191:29. doi:10.1016/j.thromres.2020.04.023
72. Akima S, McClintock C, Hunt BJ. RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1489–1495
73. Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:424–432. doi:10.1002/jmv.25685
74. Gralinski LE, Sheahan TP, Morrison TE, et al. Supplement contribution to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9:e01753–e01718. doi:10.1128/mBio.01753-18
75. Ristano AM, Mastellos DC, Huber-Lang M, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20(6):343–349. doi:10.1038/s41577-020-0320-7
76. Read SA, Obeid S, Ahlenstiel C, et al. The role of zinc in antiviral immunity. Adv Nutr. 2019;10:696–710. doi:10.1093/advances/nmz013
77. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117:9490–9496. doi:10.1073/pnas.2004181117
78. Perotti C, Del Fante C, Baldantoni F, et al. Plasma from donors recovered from the COVID-19 (COVID-19 plasma study): a multicentre study protocol. Intern Emerg Med. 2020. doi:10.1007/s11739-020-02384-2
79. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020. doi:10.1001/jama.2020.10044
80. Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;3:382–385. doi:10.1002 emm.21751.202079069
81. Prokop S, Dubrovinova E, Suser S, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020;130:733–747. doi:10.1172/JCI112127
82. Oh HL, Chia A, Chang CX, et al. Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope. J Virol. 2021;85:10464–10471. doi:10.1128/JVI.05039-11
83. Kim YC, Dema B, Reyes-Sandoval A. COVID-19 vaccines: breaking record times to first-in-human trials. NPJ Vaccines. 2020;5:34. doi:10.1038/s41541-020-0188-3
84. Angelico R, Trapani S, Manzia TM, et al. The COVID-19 outbreak in Italy: initial implications for organ transplantation programs. Am J Transplant. 2020;20:1780–1784. doi:10.1111/ajt.15904
85. Boyarsky BJ, Po-Yu Chiang T, Werbel WA, et al. Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplant. 2020;20:1800–1818. doi:10.1111/ajt.15965
86. Loupuy A, Aubert O, Revese P, et al. Organ procurement and transplant during the COVID-19 pandemic. Lancet. 2020;395:e95–e96. doi:10.1016/S0140-6736(20)31040-0
87. Kumar D, Manuel O, Natori Y, et al. COVID-19: a global transplant perspective on successfully navigating a pandemic. Am J Transplant. 2020;20:1773–1779. doi:10.1111/ajt.15876
88. Kates OS, Fisher CE, et al. Use of SARS-CoV-2 infected deceased organ donors: should we always “just say no?”. Am J Transplant. 2020;20:1787–1794. doi:10.1111/ajt.16000
89. Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfusion Med Rev. 2020;34:75–80. doi:10.1016/j.tmrv.2020.02.003
90. UNOS. COVID-19’s impact on organ donation and transplantation discussed at multi-society webinar. UNOS website. 2020. Available at https://unos.org/news/covid-19-impact-on-organ-donation-and-transplantation/. Accessed May 20, 2020.
91. Gross O, Moerer O, Weber M, et al. COVID-19-associated nephritis: early warning for disease severity and complications? Lancet. 2020;395:e87–e88. doi:10.1016/S0140-6736(20)31041-2
92. Shah MB, Lynch RJ, El-Haddad H, et al. Utilization of deceased donors during a pandemic: argument against using SARS-CoV-2 positive donors. Transplantation. 2020;109:1813–1819. doi:10.1097/TP.0000000000002456
93. Vigneswaran Y, Prachand VN, Posner MC, et al. What is the appropriate use of laparoscopy over open procedures in the current COVID-19 climate? J Gastrointest Surg. 2020;1–6. doi:10.1007/s11605-020-04592-9
94. Ritschl PV, Neumann N, Wiering L, et al. Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: a by-proxy society recommendation consensus approach. Am J Transplant. 2020;20:1826–1836. doi:10.1111/ajt.15933
95. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. JAMA Intern Emerg Med. 2020;2:2020. doi:10.1001/jamainternemergmed.2020.2250
96. Fan J, Liu X, Pan W, et al. Epidemiology of 2019 novel coronavirus disease-19 in Gansu Province, China, 2020. J Clin Invest. 2020;2020:e96. doi:10.1016/S0021-9150(20)30760-6
97. Prockop S, Doubrovina E, Suser S, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020;130:733–747. doi:10.1172/JCI112127
98. Oh HL, Chia A, Chang CX, et al. Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope. J Virol. 2021;85:10464–10471. doi:10.1128/JVI.05039-11
99. Kim YC, Dema B, Reyes-Sandoval A. COVID-19 vaccines: breaking record times to first-in-human trials. NPJ Vaccines. 2020;5:34. doi:10.1038/s41541-020-0188-3